
## Ingrid E C Verhaart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1124333/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Author's Response to: Rebuttal to: Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy, Verhaart et al. 2020. Journal of Neuromuscular Diseases, 2021, 8, 867-868.	1.1	1
2	7′,5′-alpha-bicyclo-DNA: new chemistry for oligonucleotide exon splicing modulation therapy. Nucleic Acids Research, 2021, 49, 12089-12105.	6.5	6
3	Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2020, 8, 1-19.	1.1	9
4	Safety issues and harmful pharmacological interactions of nutritional supplements in Duchenne muscular dystrophy: considerations for Standard of Care and emerging virus outbreaks. Pharmacological Research, 2020, 158, 104917.	3.1	9
5	Muscle biopsies in clinical trials for Duchenne muscular dystrophy – Patients' and caregivers' perspective. Neuromuscular Disorders, 2019, 29, 576-584.	0.3	17
6	Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F. PLoS ONE, 2019, 14, e0220665.	1.1	14
7	Therapeutic developments for Duchenne muscular dystrophy. Nature Reviews Neurology, 2019, 15, 373-386.	4.9	265
8	A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy. PLoS ONE, 2019, 14, e0215335.	1.1	2
9	Meeting on data sharing for Duchenne 21–22 March 2019 Amsterdam, the Netherlands. Neuromuscular Disorders, 2019, 29, 800-810.	0.3	3
10	Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy. PLoS ONE, 2018, 13, e0194636.	1.1	10
11	A multi-source approach to determine SMA incidence and research ready population. Journal of Neurology, 2017, 264, 1465-1473.	1.8	98
12	Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review. Orphanet Journal of Rare Diseases, 2017, 12, 124.	1.2	391
13	Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods. Journal of Neuromuscular Diseases, 2016, 3, 77-90.	1.1	13
14	The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 20MePS Antisense Oligonucleotides in mdx Mice. Molecular Therapy - Nucleic Acids, 2014, 3, e148.	2.3	28
15	A 3-base pair deletion, c.9711_9713del, in DMD results in intellectual disability without muscular dystrophy. European Journal of Human Genetics, 2014, 22, 480-485.	1.4	30
16	Low dystrophin levels in heart can delay heart failure in mdx mice. Journal of Molecular and Cellular Cardiology, 2014, 69, 17-23.	0.9	47
17	Dose-Dependent Pharmacokinetic Profiles of 2â€2- <i>O</i> -Methyl Phosphorothioate Antisense Oligonucleotidesin <i>mdx</i> Mice. Nucleic Acid Therapeutics, 2013, 23, 228-237.	2.0	23
18	DMD transcript imbalance determines dystrophin levels. FASEB Journal, 2013, 27, 4909-4916.	0.2	30

INGRID E C VERHAART

#	Article	IF	CITATIONS
19	Gene therapy for Duchenne muscular dystrophy. Current Opinion in Neurology, 2012, 25, 588-596.	1.8	34
20	Prednisolone Treatment Does Not Interfere with 2′- <i>O</i> -Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy. Human Gene Therapy, 2012, 23, 262-273.	1.4	14
21	Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. Neuromuscular Disorders, 2012, 22, 418-426.	0.3	19
22	Circulating specific antibodies enhance systemic crossâ€priming by delivery of complexed antigen to dendritic cells in vivo. European Journal of Immunology, 2012, 42, 598-606.	1.6	39
23	The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy. PLOS Currents, 2012, 4, .	1.4	4